RBC Capital raised the firm’s price target on Tenet Healthcare (THC) to $183 from $174 and keeps an Outperform rating on the shares after its Q3 results. The company saw solid recovery from recent weakness across the hospital segment following a solid Q3 beat and guidance raise, the analyst tells investors in a research note. Tenet’s early views on 2025 also suggest continuation of strong volume trends into next year and continued capacity expansion, the firm added.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on THC:
- Tenet Healthcare Reports Strong Q3 Results and Raises Outlook
- McDonald’s, Ford, Pfizer report Q3 earnings beats: Morning Buzz
- Tenet Healthcare reports Q3 adjusted EPS $2.93 vs. $1.44 last year
- Tenet Healthcare raises FY24 adjusted EPS view to $11.12-$11.73
- Tenet Healthcare sees Q4 adjusted EPS $2.20-$3.24